Ken Griffin’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-11,219
Closed -$224K 16053
2022
Q3
$224K Sell
11,219
-1,086,525
-99% -$14.3M ﹤0.01% 10183
2022
Q2
$7.56M Buy
1,097,744
+677,615
+161% +$4.76M ﹤0.01% 3068
2022
Q1
$3.91M Buy
420,129
+349,997
+499% +$3.73M ﹤0.01% 4658
2021
Q4
$998K Buy
+70,132
New +$1.21M ﹤0.01% 7963
2021
Q2
Sell
-24,555
Closed -$688K 14765
2021
Q1
$688K Sell
24,555
-12,791
-34% -$462K ﹤0.01% 8980
2020
Q4
$1.3M Buy
+37,346
New +$1.63M ﹤0.01% 6232

Ken Griffin's FMTX Position: Q4 2022 in Review

Ken Griffin sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 11,219 shares — an estimated $224K sold.

Ken Griffin first reported a position in FMTX in Q4 2020 and held it in 6 quarters. The position peaked at $7.56M in Q2 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

  • Ken Griffin reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ken Griffin sold 11,219 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $224K.
  • Ken Griffin first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
  • Ken Griffin's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $7.56M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.